Is Aspirin a Vasodilator? How It Affects Blood Vessels

Aspirin is not a vasodilator in the traditional sense. Unlike drugs such as nitroglycerin or calcium channel blockers, which directly relax blood vessel walls, aspirin works on the vascular system through a tangle of indirect mechanisms that can, under certain conditions, produce vasodilator-like effects. The distinction matters because people sometimes assume aspirin “opens up” blood vessels the way a purpose-built vasodilator does, and that misunderstanding can lead to poor decisions about medication. The reality is more interesting: aspirin influences blood vessel tone through at least three separate biochemical routes, and the net effect depends on the dose, the specific vascular bed, and the health of the blood vessel lining.

Why Aspirin Gets Confused With a Vasodilator

The confusion starts with prostaglandins. Aspirin’s best-known action is blocking the enzyme cyclooxygenase, which is the starting point for producing a family of signaling molecules called prostaglandins. Among those molecules are thromboxane A2, which constricts blood vessels and promotes clotting, and prostacyclin, which dilates blood vessels and discourages clotting. Aspirin shuts down both at the same time.

¹

This creates a paradox. Aspirin removes a vasoconstrictor signal (thromboxane) and a vasodilator signal (prostacyclin) simultaneously. If the net effect were purely the sum of those two losses, the impact on vessel tone would be close to a wash, or even slightly constrictive in some settings. But the body doesn’t work that neatly. The relative balance between thromboxane and prostacyclin varies by tissue, by disease state, and by dose. In atherosclerotic vessels, for example, the constrictor arm tends to dominate, which means removing it with aspirin can shift the balance toward relaxation. In healthy vessels, the trade-off is more even.

Aspirin Triggers Nitric Oxide Release

The prostaglandin story is only the opening chapter. Research has shown that aspirin directly stimulates the release of nitric oxide from the cells lining blood vessels. Nitric oxide is one of the body’s most potent natural vasodilators; it diffuses into the smooth muscle surrounding a vessel and causes it to relax, widening the vessel and improving blood flow.

One study using porcine coronary arteries found that aspirin triggered an immediate, dose-dependent burst of nitric oxide from the vessel lining, and it amplified the nitric oxide response to other stimuli as well. The mechanism appeared to be aspirin physically modifying the nitric oxide synthase enzyme through acetylation, boosting its output by roughly 40 to 80 percent in laboratory conditions. This was independent of aspirin’s effect on cyclooxygenase; the aspirin metabolite salicylic acid, which lacks the acetylating ability, did not produce the same effect.

²

Separate work confirmed that aspirin directly stimulates nitric oxide synthase activity without changing how much of the enzyme cells produce, and that the increased nitric oxide output helps protect endothelial cells from oxidative damage.

³

This nitric oxide pathway is probably the strongest argument for calling aspirin vasodilator-adjacent. It genuinely relaxes blood vessels, but through an indirect trigger rather than the direct smooth-muscle relaxation that defines classic vasodilators.

The Antioxidant Route to Better Vessel Function

A third mechanism complicates the picture further. Blood vessels that are under oxidative stress lose their ability to relax properly because free radicals destroy nitric oxide before it can do its job. Aspirin has been shown to reduce that oxidative burden in several ways, effectively unblocking the body’s own vasodilatory machinery.

In rats with high blood pressure, long-term aspirin treatment cut the production of damaging superoxide radicals in the aorta by roughly 27 percent in normal rats and 45 percent in hypertensive ones, and it significantly improved the vessels’ ability to relax in response to acetylcholine.

⁴

Similar findings have emerged in models of high cholesterol, where aspirin restored normal endothelial function and reduced markers of free-radical damage.

⁵

Even in aged, estrogen-depleted rats used to model postmenopausal vascular stiffness, aspirin improved relaxation and antioxidant capacity.

⁶

A related pathway involves aspirin boosting levels of an enzyme called heme oxygenase-1 in endothelial cells. In cultured human endothelial cells, aspirin increased this enzyme up to fivefold and boosted production of carbon monoxide and bilirubin, both of which have vessel-relaxing and antioxidant properties.

⁷

None of these antioxidant effects make aspirin a vasodilator in the pharmacological definition, but they do mean aspirin can restore vasodilation in vessels that have lost the ability to relax on their own.

Why Aspirin Doesn’t Actually Lower Blood Pressure

If aspirin promotes nitric oxide release, reduces oxidative stress, and helps vessels relax, you might expect it to lower blood pressure. It doesn’t, at least not in any clinically meaningful way. A 2024 systematic review and meta-analysis pooling data from trials of aspirin in hypertensive patients found no significant effect on either systolic or diastolic blood pressure.

⁸

A randomized crossover trial also tested whether taking aspirin at bedtime, rather than in the morning, might reveal a hidden blood-pressure-lowering effect. It didn’t. The difference in blood pressure between bedtime and morning dosing was essentially zero.

⁹

The likely explanation is that aspirin’s simultaneous removal of prostacyclin (a vasodilator) partially cancels out the vessel-relaxing effects from nitric oxide and antioxidant pathways. Blood pressure is also controlled by so many overlapping systems, including the kidneys, the nervous system, and circulating hormones, that the modest vascular effects of aspirin get drowned out.

What Aspirin Does to Endothelial Function

Even though aspirin doesn’t budge the blood pressure reading, it does improve a more subtle measure of vascular health called flow-mediated dilation. This test measures how much an artery widens after a brief period of restricted blood flow, a kind of stress test for the vessel lining. Poor flow-mediated dilation is an early warning sign of cardiovascular disease.

In a study of hypertensive patients, aspirin improved flow-mediated dilation from about 6.4 percent to 10.4 percent, a clinically significant gain.

¹⁰

Another trial confirmed that flow-mediated dilation improved in both healthy controls and hypertensive patients after aspirin treatment, and the improvement held even in patients classified as “aspirin resistant” by platelet tests.

¹¹

In patients with atherosclerosis, aspirin specifically improved vasodilation triggered by acetylcholine, which depends on the vessel lining being healthy enough to produce nitric oxide. Aspirin reduced femoral vascular resistance by about 19 percent at the highest acetylcholine dose, but it had no effect on vasodilation triggered by drugs that bypass the endothelium entirely.

¹²

This is a strong clue to what aspirin is actually doing: it helps the vessel lining work better rather than directly forcing smooth muscle to relax.

Dose Matters More Than You’d Think

The idea that low-dose aspirin preferentially blocks thromboxane while sparing prostacyclin has been around for decades, but it has been hard to prove definitively in humans. Animal work has shed some light on why dose is so important for vascular effects. In a study of stroke-prone hypertensive rats, a high dose improved vascular dysfunction but simultaneously triggered immune activation, kidney inflammation, and paradoxically raised blood pressure. A lower dose preserved the heart-protective effects while avoiding those problems, and it even reduced kidney scarring.

¹³

This has practical implications. The standard “baby aspirin” dose of 75 to 100 milligrams daily sits in the range thought to preferentially suppress thromboxane while leaving enough prostacyclin intact to support healthy vessel function. Higher doses, like the 650 to 1000 milligrams used for pain relief, knock out both pathways more completely, which may negate some of the vascular benefit.

Specific Vascular Beds Respond Differently

Aspirin’s vascular effects are not uniform across the body. Different tissues have different balances of prostaglandins, different levels of nitric oxide synthase, and different exposure to oxidative stress, so aspirin’s net effect varies by location.

Skin Microcirculation

In the tiny blood vessels of the skin, aspirin appears to genuinely improve flow. A crossover study found that after seven days of aspirin, the velocity of red blood cells in skin capillaries increased significantly both at rest and during the hyperemia that follows a brief blood-flow restriction. The placebo phase showed no such change.

¹⁴

Interestingly, aspirin’s effect on skin blood flow also explains why it reduces the flushing that many people experience with niacin. That flushing is driven by prostaglandins dilating skin blood vessels, and aspirin blocks that prostaglandin pathway. In a trial of 148 men, aspirin cut the incidence of niacin-induced flushing and reduced its intensity and duration by about 30 to 40 percent.

¹⁵

So in the skin, aspirin can either increase microvascular flow or block prostaglandin-driven flushing, depending on the context. The same drug produces opposite-seeming effects in the same tissue, because the underlying triggers differ.

Erectile Function

Blood flow to the penis depends heavily on nitric oxide and healthy endothelial function, and aspirin’s effects on both have prompted researchers to investigate it as a potential treatment for erectile dysfunction caused by vascular problems. A meta-analysis of randomized controlled trials found that aspirin significantly improved erectile function scores compared to placebo.

¹⁶

In one of those trials, men with vascular erectile dysfunction who took 100 milligrams of aspirin daily for six weeks saw their erectile function scores improve more than threefold compared to placebo.

¹⁷

This is still early-stage evidence, and aspirin is nowhere near approved for this use, but the results align with what aspirin’s vascular mechanisms would predict.

Lung Blood Vessels

The lungs present a case where aspirin can actually enhance vasoconstriction rather than promote relaxation. When oxygen levels in a section of lung drop, the blood vessels there normally constrict to divert blood to better-ventilated areas, a reflex called hypoxic pulmonary vasoconstriction. Some individuals and animals are “weak reactors” to this reflex. Aspirin, by blocking vasodilatory prostaglandins that oppose the constriction, enhanced this reflex fourfold in weak-reacting dogs and restored it in non-responders.

^{18 19}

This is about as far from vasodilation as you can get: in the lungs, aspirin strengthens the constrictor response. It’s a vivid illustration of why labeling aspirin as simply a “vasodilator” or “vasoconstrictor” misses the point entirely.

How Aspirin Interferes With ACE Inhibitors

One area where aspirin’s vascular effects have real clinical consequences is its interaction with ACE inhibitors, drugs commonly prescribed for heart failure and high blood pressure. ACE inhibitors work partly by boosting levels of bradykinin, which in turn stimulates vasodilating prostaglandins. Because aspirin blocks prostaglandin production, it can blunt this part of an ACE inhibitor’s effect.

²⁰

In a double-blind trial comparing aspirin and ticlopidine alongside enalapril (an ACE inhibitor), patients on ticlopidine saw significant drops in systemic vascular resistance, while the aspirin group did not.

²¹

This interaction has been debated for years. The clinical significance is still argued over, but it’s a genuine pharmacological effect: aspirin can partially counteract the vasodilation that ACE inhibitors are trying to produce. If you are on both medications, this interaction is worth being aware of, though it doesn’t mean you should stop either one without medical guidance.

Coronary Arteries and Vasospasm

In the heart’s own blood vessels, aspirin plays a nuanced role. By suppressing thromboxane, aspirin reduces platelet-driven constriction of coronary arteries. In an elegant experiment using isolated human coronary arteries, platelets from aspirin-treated donors caused far less arterial contraction than platelets from untreated donors, and thromboxane levels in the organ bath dropped correspondingly.

²²

However, there has been a lingering question about whether aspirin might paradoxically promote coronary artery spasm by removing the protective prostacyclin signal. A Korean observational study found a higher incidence of coronary spasm among patients already taking aspirin, though the authors were careful to note that the association was likely confounded by baseline differences and should not be taken as proof of causation.

²³

The consensus remains that aspirin’s coronary benefits, mainly through platelet inhibition, far outweigh any theoretical spasm risk, which is why it remains a cornerstone of treatment after heart attacks.

When Aspirin’s Vascular Effects Don’t Work

Not everyone gets the same vascular response from aspirin. The concept of “aspirin resistance,” where standard doses fail to suppress platelet activity adequately, extends to the vascular lining as well. Research has found that people classified as aspirin-resistant on platelet tests also tend to have worse endothelial function. In patients with stable coronary disease, endothelial dysfunction was identified as one mechanism underlying aspirin resistance.

²⁴

Even in young, apparently healthy men, those with aspirin resistance showed reduced flow-mediated dilation compared to aspirin-sensitive peers. The reduced vasodilation appeared to stem from increased nitric oxide degradation by oxidative stress and altered lipid profiles.

²⁵

This creates a frustrating catch-22: the people whose vessels are most damaged, and who would theoretically benefit most from aspirin’s vascular effects, may be the least likely to respond to it. Aspirin’s ability to promote nitric oxide and reduce oxidative stress depends on having a vessel lining that’s functional enough to respond. When the endothelium is too far gone, aspirin’s indirect vasodilatory mechanisms have less raw material to work with.

Aspirin in Pregnancy and Placental Blood Flow

One of the most widely studied clinical applications of aspirin’s vascular effects is in pregnancy, specifically for preventing preeclampsia. The idea is that low-dose aspirin shifts the thromboxane-prostacyclin balance in the placental vessels, improving blood flow to the developing baby. The evidence, though, is decidedly mixed.

One trial of women with abnormal uterine artery blood flow found that aspirin cut the incidence of preeclampsia dramatically, from about 23 percent in the placebo group to 2.5 percent in the aspirin group.

²⁶

But other trials have been far less encouraging. A randomized trial starting aspirin at 23 weeks found no difference in preeclampsia rates between aspirin and placebo groups.

²⁷

A more recent trial in first-time mothers identified as high-risk by early ultrasound also found that low-dose aspirin was not associated with a lower rate of preeclampsia.

²⁸

The timing of aspirin initiation appears to matter. Larger meta-analyses not in this source set have generally shown benefit when aspirin is started before 16 weeks of gestation, which aligns with the theory that it works by improving placental vessel development rather than dilating already-formed vessels. By the time abnormal blood flow is detectable later in pregnancy, the window for aspirin to reshape the vascular architecture may have closed. This is another reminder that aspirin’s relationship with blood vessels is about facilitating healthy function over time, not about immediate dilation on demand.

Aspirin’s Effect on Smooth Muscle Nitric Oxide

Beyond the endothelial lining, aspirin also influences the smooth muscle cells that form the vessel wall itself. In laboratory conditions, aspirin and related drugs boosted nitric oxide production in inflamed smooth muscle cells at concentrations achievable with normal therapeutic dosing. The mechanism involved upregulating the inducible form of nitric oxide synthase through a pathway unrelated to cyclooxygenase inhibition.

²⁹

This is relevant because inflamed blood vessels, the kind found in atherosclerosis, express high levels of inflammatory signaling molecules. In that setting, aspirin may promote nitric oxide production directly within the vessel wall, adding yet another layer to its vascular repertoire. Whether this contributes meaningfully to aspirin’s clinical benefits in cardiovascular disease is still being sorted out, but it helps explain why aspirin’s effects on the vasculature are so much broader than its textbook description as “just an anti-platelet drug” would suggest.